Recombinant 9-valent human papillomavirus (6/11/16/18/31/33/45/52/58) vaccine (kangle biotechnology)

重组九价人乳头瘤病毒（6/11/16/18/31/33/45/52/58型）疫苗（大肠埃希菌，北京康乐卫士生物）

Report date: 2026/03/09 20:02:04

Base Information

Drug NameRecombinant 9-valent human papillomavirus (6/11/16/18/31/33/45/52/58) vaccine (kangle biotechnology)

Drug Alias NameN/A

ClassificationVaccines > Vaccine type > Multivalent vaccineVaccines > Biological material > Viral vaccineVaccines > Application > Prophylactic vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsAnal intraepithelial neoplasiaNephritis, InterstitialGenital Diseases, Male +[11]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIndonesiaMainland China

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaPhase 3 Clinical

Originator CompaniesBeijing Health Guard Biotechnology Inc

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Health Guard Biotechnology Inc

Inactive CompaniesN/A

Active IndicationsAnal intraepithelial neoplasiaNephritis, InterstitialGenital Diseases, Male +[11]

Inactive IndicationsN/A

Other Information

ATC CodeN/A